Pancreatic ductal adenocarcinoma is highly resistant to systemic chemotherapy. Although there are many reports using pancreatic cancer cells derived from patients who did not receive chemotherapy, characteristics of pancreatic cancer cells from chemotherapy-resistant patients remain unclear. In this study, we set out to establish a cancer cell line in disseminated cancer cells derived from gemcitabine-resistant pancreatic ductal adenocarcinoma patients. By use of in vitro co-culture system with stromal cells, we established a novel pancreatic tumor-initiating cell line. The cell line required its direct interaction with stromal cells for its in vitro clonogenic growth and passaging. Their direct interaction induced basal lamina-like extrace...
The prognosis of pancreatic ductal adenocarcinoma (PDAC) is exceedingly poor. Although surgical rese...
OBJECTIVES: Pancreatic cancer still remains a challenge for its biological complexity and lack of ef...
Cancer stem cells (CSCs) typically have the capacity to evade chemotherapy and may be the principal ...
Pancreatic ductal adenocarcinoma is highly resistant to systemic chemotherapy. Although there are ma...
Pancreatic ductal adenocarcinoma (PDAC) is often diagnosed when metastatic events have occurred. Can...
Pancreatic adenocarcinoma (PDAC) is one of the most aggressive and devastating human malignancies wi...
ABSTRACT: BACKGROUND: Therapy resistance remains one of the major challenges to improve the prognosi...
Cancer stem cells (CSCs) have been proposed to underlie the initiation and maintenance of tumor grow...
AbstractNo systemic therapy is effective against pancreatic cancer (PC). Pancreatic cancer stem cell...
Pancreatic cancer (PC) remains one of the most lethal human malignancies with poor prognosis. Despit...
SummaryPancreatic adenocarcinoma is currently the fourth leading cause for cancer-related mortality....
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most difficult to treat major cancers, wi...
Abstract Background Pancreatic ductal adenocarcinomas are among the most malignant neoplasms and hav...
Pancreatic ductal adenocarcinoma (PDAC) has an extremely poor response to chemo- and (modest-dose co...
Pancreatic adenocarcinoma is currently the fourth leading cause for cancer-related mortality. Stem c...
The prognosis of pancreatic ductal adenocarcinoma (PDAC) is exceedingly poor. Although surgical rese...
OBJECTIVES: Pancreatic cancer still remains a challenge for its biological complexity and lack of ef...
Cancer stem cells (CSCs) typically have the capacity to evade chemotherapy and may be the principal ...
Pancreatic ductal adenocarcinoma is highly resistant to systemic chemotherapy. Although there are ma...
Pancreatic ductal adenocarcinoma (PDAC) is often diagnosed when metastatic events have occurred. Can...
Pancreatic adenocarcinoma (PDAC) is one of the most aggressive and devastating human malignancies wi...
ABSTRACT: BACKGROUND: Therapy resistance remains one of the major challenges to improve the prognosi...
Cancer stem cells (CSCs) have been proposed to underlie the initiation and maintenance of tumor grow...
AbstractNo systemic therapy is effective against pancreatic cancer (PC). Pancreatic cancer stem cell...
Pancreatic cancer (PC) remains one of the most lethal human malignancies with poor prognosis. Despit...
SummaryPancreatic adenocarcinoma is currently the fourth leading cause for cancer-related mortality....
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most difficult to treat major cancers, wi...
Abstract Background Pancreatic ductal adenocarcinomas are among the most malignant neoplasms and hav...
Pancreatic ductal adenocarcinoma (PDAC) has an extremely poor response to chemo- and (modest-dose co...
Pancreatic adenocarcinoma is currently the fourth leading cause for cancer-related mortality. Stem c...
The prognosis of pancreatic ductal adenocarcinoma (PDAC) is exceedingly poor. Although surgical rese...
OBJECTIVES: Pancreatic cancer still remains a challenge for its biological complexity and lack of ef...
Cancer stem cells (CSCs) typically have the capacity to evade chemotherapy and may be the principal ...